Title

Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
A Randomized, Two-Way Crossover, Single-Dose, Open Label Study to Evaluate the Relative Bioavailability of a Test Tablet Formulation of Carvedilol (25 mg), Compared to an Equivalent Dose of COREG® (SmithKline Beecham Pharmaceuticals) in 24 Fed, Healthy, Adult Subjects
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Intervention/Treatment

    carvedilol ...
  • Study Participants

    24
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals) in a test population of 24 adult individuals under fed conditions.
Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods
Study Started
Dec 31
2001
Primary Completion
Dec 31
2001
Study Completion
Dec 31
2001
Results Posted
Aug 18
2009
Estimate
Last Update
Sep 15
2009
Estimate

Drug Carvedilol 25 mg tablets

1 x 25 mg

Drug COREG® 25 mg tablets

1 x 25 mg

Carvedilol Experimental

Carvedilol 25 mg Tablet (test) dosed in first period followed by Coreg® 25 mg Tablet (reference) dosed in second period

Coreg® Active Comparator

Coreg® 25 mg Tablet (reference) dosed in first period followed by Carvedilol 25 mg Tablet (test) dosed in second period

Criteria

Inclusion Criteria:

Sex: Male of Female; similar proportions of each preferred.
Age: At least 18 years.
Weight: Minimum of 120 pounds and a BMI (body mass index) of less than 30.

Exclusion Criteria:

Subjects not complying with the above inclusion criteria must be excluded from the study.
In addition, any one of the conditions listed below will exclude a subject from the study.
History of treatment for alcoholism, substance abuse, or drug abuse within the past 24 months
History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
History of treatment for any gastrointestinal disorder within the past five (5) years.
History of, or presence of, asthma
History of peripheral vascular disease
History of heart failure
History of pre-existing cardiac arrythmias associated with tachycardia
History of severe sensitivity to allergens, requiring urgent medical treatment.
Females who are pregnant or lactating
History of hypersensitivity to carvedilol, or any beta adrenergic blocking drug.
Conditions upon screening which might contraindicate or require that caution be used in the administration of carvedilol, including:
sitting systolic blood pressure below 100 mmHg, or diastolic pressure below 60 mmHg.
Heart rate less than 60 beats per minute after a 5-minute rest in a seated position.
Inability to read and/or sign the consent form.
Treatment with any other investigational drug during the four (4) weeks prior to the initial dosing for this study.
Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums,etc.) Ninety (90) days abstinence is required.
subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.

Summary

All Events

Event Type Organ System Event Term

Cmax - Maximum Observed Concentration - Carvedilol in Plasma

Bioequivalence based on Cmax

Carvedilol

89.91
ng/mL (Mean)
Standard Deviation: 40.86

Coreg®

97.05
ng/mL (Mean)
Standard Deviation: 49.61

AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Carvedilol in Plasma

Bioequivalence based on AUC0-inf

Carvedilol

467.57
ng*h/mL (Mean)
Standard Deviation: 287.12

Coreg®

490.16
ng*h/mL (Mean)
Standard Deviation: 337.58

AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Carvedilol in Plasma

Bioequivalence based on AUC0-t

Carvedilol

455.91
ng*h/mL (Mean)
Standard Deviation: 284.99

Coreg®

478.61
ng*h/mL (Mean)
Standard Deviation: 336.07

Total

24
Participants

Age, Categorical

Race/Ethnicity, Customized

Region of Enrollment

Sex: Female, Male

First Intervention

Carvedilol (Test) First

Coreg® (Reference) First

Washout: 7 Days

Carvedilol (Test) First

Coreg® (Reference) First

Second Intervention

Carvedilol (Test) First

Coreg® (Reference) First

Drop/Withdrawal Reasons

Coreg® (Reference) First